The problem you’ve been putting off usually has a straightforward answer.

Ask for the exclusions rather than the price. The number is easy; the list of what it does not contain is where the surprises live.

UK private providers have been required to publish price information through PHIN since the Competition and Markets Authority reforms, and yet the evidence is that price information remains hard for patients to reach and often incomplete. Across the wider price-transparency literature, patients who do use pricing tools tend to choose less costly providers — but uptake is low, and most published prices describe a single service at list rate rather than what one episode of care will actually cost one person.

That is the whole problem in a sentence. A surgeon’s fee is not a price. The question that produces a usable answer is: does this figure include the surgeon, the anaesthetist, the hospital facility fee, routine bloods, imaging, any implant or consumable, follow-up appointments, and a defined period of cover if there is a complication? Bundled, patient-specific episode pricing is what the evidence supports as the format that actually prevents bill shock. Anything short of it leaves a gap, and the gap is always filled at your expense.

Araich 2023, Br J Radiol, price transparency in North America and Europe · AMA J Ethics 2022, which price should be transparent · Zhang 2020, Health Policy, scoping review of price transparency · Sabanovic 2023.

This is the single most expensive thing to leave unwritten, and the one most often left unwritten.

Complications are not merely unpleasant; they are the point at which apparently affordable care becomes unaffordable. In a large claims analysis, patients who had a complication stayed 12.4 days rather than 3.9, and the additional cost outran the additional payment. A study in JAMA Surgery found mean hospital costs $19,626 higher where a complication occurred. Those are American figures and the arithmetic does not transfer to the UK — but the shape does, and a UK service evaluation of private-sector cosmetic complications referred on to one London NHS plastics unit put the cost of fourteen patients in a single year at £16,471, borne by the NHS rather than by the provider who operated.

So the question is not “what is your complication rate” alone. It is: what specifically is covered, for how long, and by whom — readmission, a return to theatre, a revision procedure, an extended stay, critical care, and the follow-up that goes with them? Get the period in writing with a date on it. Most UK fixed-price packages include some defined complication cover; they differ enormously in its length and in what sits outside it.

Haidar 2023, J Comp Eff Res, Medicare claims · Healy 2016, JAMA Surgery · Br J Surg 2021, cosmetic surgery complications referred to a London tertiary plastics service · Venditto 2020; Yu 2026.

“Do you take Bupa?” is not the question. Whether every clinician in your pathway is fee-assured with your insurer is.

Having insurance and being fully covered are different things. In one audit of billing for privately insured inpatients, 98.5% still had some out-of-pocket spending, and half paid up to 30% of the episode themselves. In a US analysis of more than five million admissions, patients treated at an in-network hospital still received an out-of-network bill in up to 42% of inpatient cases — because the hospital was in-network and one of the clinicians was not. Even after legislation designed to stop that, overall high-burden medical spending did not clearly fall.

The British version of this is the shortfall: your insurer pays its scheduled rate, the consultant charges more, and you receive the difference. It is entirely legal and entirely avoidable if you ask first. The three questions that prevent it are: is every clinician in this pathway — surgeon, anaesthetist, radiologist, pathologist — fee-assured with my insurer? What pre-authorisation code have you submitted, and has it been accepted? And is any part of this likely to be treated as a pre-existing condition or as chronic rather than acute? Ask before the appointment, not before the operation.

Sugunan 2024, AIMS Public Health, hospital billing audit · Sun 2019, JAMA Intern Med, out-of-network billing at in-network hospitals, n = 5,457,981 admissions · Liu 2025, BMJ, spending after the No Surprises Act · Amporfu 2023; Ng 2024.

The most reliably predictive question you can ask, and the one most often answered with a number about years rather than a number about cases.

The volume–outcome relationship is among the most reproducible findings in surgical research. A systematic review of systematic reviews found that most reviews support it; a scoping review found a statistically significant association in 86.6% of studies examining it. The clearest British illustration comes from the National Joint Registry linked to Hospital Episode Statistics — 39,281 shoulder replacements by 638 consultants across 416 units — where surgeons averaging fewer than 10.4 procedures a year carried up to 1.94 times the revision risk of the lowest-risk surgeons. In radical prostatectomy specifically, higher-volume surgeons are associated with lower mortality, morbidity, complications, readmission and cost.

Two honest qualifications. Volume is a proxy, not a measurement: a high-volume surgeon can still be a poor one, and the association is stronger for some operations than others. And any individual surgeon’s complication rate for a rare event is statistically fragile — at a true rate of 2%, a personal series of 300 cases gives a figure with a confidence interval wide enough to cover most honest answers. What genuinely tells you something is whether the surgeon audits at all, what the denominator is, and whether the reply is a number or a mood.

Morche 2016, systematic review of systematic reviews · Levaillant 2021, scoping review · Valsamis 2023, BMJ, National Joint Registry and HES for England, n = 39,281 · Leow 2017 (radical prostatectomy) · Fischer 2023; Malik 2018; Bedi 2021.

A fair question to ask anyone who is paid by the operation, and one you should be able to test rather than take on trust.

The conflict is structural rather than personal: in private practice the person advising you on whether to have surgery is generally the person who is paid to perform it. Pretending that tension does not exist is less useful than showing you how to check. Research on private fee-setting finds that specialists themselves describe pricing as opaque and resist transparency initiatives, which is not evidence of bad faith but is evidence that the information asymmetry is real.

Three questions test it directly. What is the case against this operation? — if the answer is that there isn’t one, you are being sold something. What would happen if I did nothing for six months? — for a great many urological conditions the honest answer is “very little”, and a surgeon who cannot say so is not weighing your interests. And which of the options you have described do you not offer, and why? — a recommendation that happens to coincide exactly with the recommender’s own skill set deserves a second opinion, which no reasonable surgeon will resent you seeking.

Ranasinghe 2023, Soc Sci Med, qualitative study of fee setting and price transparency among private specialists · Araich 2023 · AMA J Ethics 2022.

Usually for time, continuity and choice. Sometimes for a genuinely different operation. It is worth knowing which one you are buying.

Reviews of elective surgery delivered by private providers generally do find shorter waits and better access — but the evidence base is largely observational, and some reviews also found healthier case mix and mixed postoperative outcomes, meaning part of the apparent advantage is who was selected rather than what was done. That is the honest version of the speed argument.

Time itself, though, is not nothing. Modelling of the NHS in England estimated real quality-adjusted life-year losses when waits lengthened from 18 to 36 weeks, concentrated in patients from more deprived areas. A matched study in South West England found patients waiting beyond 18 weeks consumed measurably more healthcare while they waited. Against that, a 2026 analysis of hip and knee replacement in England found waiting time did not significantly affect post-operative health or readmission — so the size of the benefit depends heavily on the condition, and anyone quoting one figure for all of them is generalising.

The distinction that matters for you: does the private pathway offer a technology or technique you cannot get on the NHS locally, or the same operation sooner? Both are legitimate reasons to pay. Only one of them justifies a premium over waiting.

Rathnayake 2025, review of outsourcing elective surgery · Akpinar 2023 · Gibbs 2024, Med Decis Making, NHS England waiting-time modelling · BMC Health Serv Res 2024, South West England matched cohort · Econ Hum Biol 2026, joint replacement waiting times.

Often, yes — and the honest answer is that this is not the objection it sounds like.

Most UK private consultants also hold NHS posts; I work across Oxford University Hospitals and Imperial College Healthcare alongside this practice. So the person is frequently the same person. What differs is not who, but how much of them you get, and whether they stay with you.

Three things change. The appointment is longer and it is yours. The consultant you meet is the consultant who operates — in the NHS that is often not true, not through bad faith but because lists are staffed by rota and a named surgeon on a letter is not a promise about the theatre. And continuity holds across the whole episode: the same person assesses you, operates, and sees you afterwards, which the handover literature suggests matters more than patients realise. One review of surgical handovers found a quarter were associated with care failures, and that a surgical inpatient may be seen by around ten different doctors during a single admission.

The mechanism behind faster access is also worth stating plainly, because it is rarely said aloud: where private and public patients are treated in the same system, private patients have been shown to wait substantially less and to be admitted ahead of their listing rank. That is what you are buying. Whether it is worth it is a reasonable thing to weigh, and the answer is not always yes.

Ryan 2024, surgical handover review · Lazzara 2022, Ergonomics, meta-analysis of 41 handoff studies · Johar 2010, waiting times for private and public patients in NSW public hospitals · Markovich 2026, hospital-to-community continuity.

A hospital question rather than a surgeon question, and one you should ask the hospital directly and get in writing.

Independent hospitals in the UK vary enormously in what they can manage, and the regulator has said so. When the Care Quality Commission reported on 206 independent hospitals in England, 62% were rated good and 8% outstanding — but almost a third required improvement overall, and 41% required improvement on safety specifically, which was the regulator’s single greatest concern. A more recent cross-sector study found independent hospitals scoring higher on average CQC ratings than NHS providers, while cautioning that narrower case mix and specialisation probably explain part of that difference. Both findings are true, and neither tells you about the building you would actually be admitted to.

Ask four specific things, of the hospital and not of the consultant: Is there level 3 critical care on this site, or level 2 only? Is there a resident doctor in the building overnight, and what grade? If I deteriorate, what is the transfer arrangement, to which NHS hospital, and how long does it take? And has anyone been transferred out after this operation in the past year? Many private hospitals have overnight resident medical cover without on-site intensive care, and those are genuinely different things. A hospital that answers precisely is telling you something; one that answers “we have full facilities” is telling you something else.

Iacobucci 2018, BMJ, CQC report on 206 independent hospitals in England · Bullen 2025, Int J Qual Health Care, determinants of quality in the independent and public sectors in England · Atkinson 2021, on interpreting reported infection rates alongside surveillance audit quality.

Ask for the route by name before you are discharged, not after. And be sceptical of anyone who implies no problem could ever need a different hospital.

Out-of-hours contact is common enough to plan for rather than to treat as exceptional. In one surgical cohort 23.2% of patients made after-hours calls, mostly about symptoms or practical questions — and clinician-initiated follow-up substantially reduced how many. In a private practice, improving preoperative education cut total after-hours calls by 22%, almost entirely by removing the non-urgent ones. Most such calls are not emergencies: in one series only 7.2% led to an emergency department referral, and in a helpline dataset only 11.9% were urgent, with most resolved during the call or the next working day.

The discharge period is where private care most often quietly fails. A 2025 qualitative systematic review found patients frequently feel insecure and left responsible for complex self-care at home, and that expectations shape how the whole recovery feels more than the events themselves do. Structured handover measurably helps: a meta-analysis of 41 studies found standardised post-operative handoffs improved patient outcomes with an odds ratio of 1.49.

So ask: which number do I ring at two in the morning, and who actually answers it — a ward, a colleague, or a call centre? Who do they escalate to, and how quickly? And what happens if the problem turns out to need more than this hospital can provide? That last one is the question providers are vaguest about, and the honest answer is that it occasionally happens — particularly where the problem is a medical one rather than a surgical one. Most private hospitals have no emergency department, so what a good pathway gives you is not a promise that it never happens. It is a route settled in advance: a number that answers at any hour, a named consultant it escalates to when a problem is not straightforward, and a team that arranges the move if one is needed.

Blumenthaler 2021, after-hours calls after surgery · Harbour 2023, private practice after-hours call reduction · Kofina 2022; Chong 2022 · Sig 2025, qualitative systematic review of discharge and home recovery · Lazzara 2022, Ergonomics, meta-analysis of 41 handoff studies · Duffy 2025; Ryan 2025.

Ask what the booked appointment length actually is. It is a scheduling fact, and any practice can tell you.

This sounds like a question about manner. It is really a question about outcomes. The discharge and recovery literature keeps arriving at the same finding: what patients were led to expect shapes how well the recovery feels, sometimes more than what happened to them clinically. In a study of men recovering from prostate surgery, every patient had been told bleeding was possible, but 93.5% expected it to stop within thirty days — and one who bled to day 23 was convinced something had gone badly wrong. Nothing had. The complication was in the counselling.

Which means the time is not a courtesy. It is where the questions you have already researched get answered, where your actual risk profile gets discussed rather than the average one, and where you find out what to expect closely enough that ordinary recovery does not read as disaster. If you arrive with a list, a good consultation gets through the list.

Sig 2025, qualitative systematic review of patient experience after discharge · Assmus 2021, CUAJ, patient expectations and understanding of recovery · El-Boghdadly 2024, Anaesthesia, Association of Anaesthetists and British Pain Society consensus.